Exelixis (EXEL) Change in Accured Expenses (2010 - 2026)
Exelixis' (EXEL) quarterly Change in Accured Expenses came in at $4.0 million in Q2 2026, down 12.18% year-on-year from $4.6 million in Q2 2025, and up 1039.15% quarter-over-quarter from $355000.0 in Q1 2026.
Exelixis (EXEL) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Exelixis' Change in Accured Expenses history runs 16 years deep, the most recent figure standing at $4.0 million for Q2 2026.
- On a quarterly basis, Change in Accured Expenses fell 12.18% year-over-year to $4.0 million in Q2 2026; TTM through Apr 2026 was $1.3 million, a 83.85% decrease from a year earlier, with the FY2026 full-year figure at $1.9 million, up 1374.5% from the prior year.
- Change in Accured Expenses climbed to $4.0 million in Q2 2026 per EXEL's latest filing, from $355000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $5.1 million in Q2 2023 and bottomed at -$54.3 million in Q2 2022.
- The 5-year median for Change in Accured Expenses is $604500.0 (2025), against an average of -$3.4 million.
- Across the five-year window, Change in Accured Expenses plunged 5499.1% in 2022 and jumped 223.48% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at -$54.3 million in 2022, then soared by 100.49% to $264000.0 in 2023, then jumped by 410.23% to $1.3 million in 2024, then plunged by 32.96% to $903000.0 in 2025, then soared by 347.84% to $4.0 million in 2026.
- Per Business Quant, the three latest EXEL Change in Accured Expenses figures stand at $4.0 million (Q2 2026), $355000.0 (Q1 2026), and $903000.0 (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 1.13 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -16.82 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 23.10 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 107.70 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -16.74 Mn |
| 10 | Exelixis | 14.38 Bn | 13.60 Bn | 590.86 Mn | 4.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 4.04 Mn |
| Apr 3, 2026 | 4.04 Mn |
| Jan 2, 2026 | 355,000.00 |
| Jan 2, 2026 | 355,000.00 |
| Oct 3, 2025 | 903,000.00 |
| Oct 3, 2025 | 903,000.00 |
| Jul 4, 2025 | -3.96 Mn |
| Jul 4, 2025 | -3.96 Mn |
| Apr 4, 2025 | 4.61 Mn |
| Apr 4, 2025 | 4.61 Mn |
| Jan 3, 2025 | 854,000.00 |
| Jan 3, 2025 | 854,000.00 |
| Sep 27, 2024 | 1.35 Mn |
| Sep 27, 2024 | 1.35 Mn |
| Jun 28, 2024 | 1.48 Mn |
| Jun 28, 2024 | 1.48 Mn |
| Mar 29, 2024 | -3.83 Mn |
| Mar 29, 2024 | -3.83 Mn |
| Dec 29, 2023 | 264,000.00 |
| Dec 29, 2023 | 264,000.00 |